With over 25 years of dedicated service to the life sciences industry, Cooley Godward Kronish has built one of the most integrated and comprehensive life sciences legal practices in the country. We have represented nearly 30 percent of the companies on the NASDAQ Biotechnology and BioCentury 100™ Indices and more than half of the companies on the AMEX Biotech Index. Today, we represent over 600 life sciences companies, both public and private, here in the U.S. and internationally, in nearly all aspects of their business. Our deep domain expertise also enables us to effectively and efficiently represent many venture capital clients in their investments in life sciences companies, as well as lending institutions and investment banks servicing those companies.
We bring to our client relationships a unique combination of innovative legal advice, deep industry knowledge and practical understanding of our clients’ business needs in today’s changing and challenging environment. Our track record speaks for itself:- Ranked #1 in Life Sciences by Chambers USA: America’s Leading Lawyers for Business in 2007 and 2008
- Ranked #1 in issuer-side Life Science IPOs from 2000 – present (Source: IPO Vital Signs)
- Ranked #2 in the U.S. as counsel to health care pre-IPO clients securing capital (Source: The Venture Capital Analyst, Healthcare Edition, 2006)
- Ranked #1 in the U.S. for representation of venture-backed Biotech/Pharmaceuticals companies in 2007 (Source: VentureSource)
- Handled nearly 18% of all U.S. Life Sciences IPOs from 2004 to 2007 (Source: IPO Vital Signs)
- #1 in issuer-side counsel in PIPE placements for life sciences companies since 2000
- Ranked in top 10 as underwriters’ counsel for life sciences IPOs filed from 2004-2007 (Source: IPO Vital Signs)
- Completed 123 Life Sciences public offerings, including 31 IPOs since 2002
- Closed more than 90 M&A deals for life sciences companies since 2000, with a total deal value in excess of $25 billion
Our attorneys have deep expertise across all aspects of life sciences technologies, including genomics, proteomics, drug discovery tools, vaccines, screening assays and methods, biological and small organic therapeutic compounds and uses. We have particular expertise in “cross-over” matters involving bioinformatic and other IT-implemented inventions.
Related practices
